Brent Warner
Chief Executive Officer, Board Member - Protego Biopharma
Professional Overview
Brent Warner is an accomplished biopharmaceutical executive with over 20 years of experience leading strategic initiatives and driving innovation in the gene therapy and rare disease sectors. As the Chief Executive Officer and Board Member of Protego Biopharma, he leverages his deep industry expertise to guide the company's cutting-edge research and development efforts, with a focus on developing transformative therapies for patients with rare and complex medical conditions.
Experience Summary
Current Role
As the Chief Executive Officer and Board Member of Protego Biopharma, Brent is responsible for setting the company's strategic vision, leading cross-functional teams, and fostering a culture of collaboration and continuous improvement. Under his leadership, Protego Biopharma has navigated the complex regulatory landscape, secured key partnerships, and advanced multiple promising drug candidates through the clinical pipeline.
Career Progression
Prior to his current role, Brent held senior leadership positions at some of the industry's most prominent biopharmaceutical companies. As the President of Gene Therapy at Poseida Therapeutics, he spearheaded the development and commercialization of novel gene therapies, while at Novartis, he served as the Vice President of Gene Therapy and Rare Disease, driving the company's efforts to address unmet medical needs. Brent's earlier experience also includes strategic roles at Biogen, where he was instrumental in the successful launch and global expansion of the company's rare disease portfolio.
Academic Background
Brent holds a Bachelor of Science degree in Biology and a Master of Business Administration, equipping him with a robust understanding of both the scientific and business aspects of the industry.
Areas of Expertise
- Gene therapy and rare disease drug development
- Strategic planning and execution
- Cross-functional team leadership
- Regulatory affairs and market access
- Stakeholder engagement and partnership management
Professional Impact
Throughout his career, Brent has been recognized for his ability to drive innovation and deliver measurable results. He has played a pivotal role in the successful launch and commercialization of several groundbreaking therapies, including Biogen's SPINRAZA, a first-in-class treatment for spinal muscular atrophy. Brent's commitment to advancing the field of gene therapy has also led to his appointment as a Board Member at Cure Rare Disease, where he contributes his expertise to the organization's mission of developing personalized treatments for those living with rare diseases.
Conclusion
Brent Warner's extensive experience, coupled with his strategic vision and collaborative leadership style, position him as a driving force in the biopharmaceutical industry. As the Chief Executive Officer of Protego Biopharma, he continues to push the boundaries of innovation, with the ultimate goal of improving the lives of patients and their families.
